FDA Approves Updated Pembrolizumab Indication for UC

On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved a label update to pembrolizumab for first-line advanced urothelial carcinoma (UC). This approval converts the accelerated approval of pembrolizumab to a regular approval.

Read Merck's announcement.

Posted 9/1/2021